Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice

Rationale: Sclerostin inhibition demonstrated bone anabolic potential in osteogenesis imperfecta (OI) mice, whereas humanized therapeutic sclerostin antibody romosozumab for postmenopausal osteoporosis imposed clinically severe cardiac ischemic events. Therefore, it is desirable to develop the next...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Luyao, Yu, Yuanyuan, Ni, Shuaijian, Li, Dijie, Liu, Jin, Xie, Duoli, Chu, Hang Yin, Ren, Qing, Zhong, Chuanxin, Zhang, Ning, Li, Nanxi, Sun, Meiheng, Zhang, Zong-Kang, Zhuo, Zhenjian, Zhang, Huarui, Zhang, Shu, Li, Mei, Xia, Weibo, Zhang, Zhenlin, Chen, Lin, Shang, Peng, Pan, Xiaohua, Lu, Aiping, Zhang, Bao-Ting, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373813/
https://www.ncbi.nlm.nih.gov/pubmed/35966595
http://dx.doi.org/10.7150/thno.63177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373813/
https://www.ncbi.nlm.nih.gov/pubmed/35966595
http://dx.doi.org/10.7150/thno.63177

Ejemplares similares